Crizler
Generic Name
Crizotinib
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| crizler 2 mg injection | ৳ 580.00 | N/A |
Description
Overview of the medicine
Crizotinib is an anti-cancer medication used to treat specific types of non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma (ALCL) that are characterized by certain genetic rearrangements (ALK or ROS1). It is a targeted therapy that works by inhibiting specific proteins involved in cancer cell growth.
Uses & Indications
Dosage
Adults
250 mg orally twice daily. Continue treatment until disease progression or unacceptable toxicity.
Elderly
No specific dosage adjustment recommended for elderly patients, but monitor closely for adverse reactions.
Renal_impairment
For severe renal impairment (CrCl < 30 mL/min) not requiring dialysis, reduce dose to 250 mg once daily.
How to Take
Take orally with or without food. Swallow capsules whole; do not crush, dissolve, or open capsules.
Mechanism of Action
Crizotinib is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) receptor tyrosine kinases. By binding to and inhibiting these abnormal proteins, which are often overactive in certain cancers, crizotinib blocks cell signaling pathways that promote cancer cell growth and survival, leading to tumor regression.
Pharmacokinetics
Onset
Clinical response typically observed within weeks of treatment initiation, not a rapid onset like acute medications.
Excretion
Primarily through feces (approximately 60%) and urine (approximately 20%), mostly as metabolites.
Half life
Approximately 10-25 hours (mean effective half-life).
Absorption
Rapidly absorbed; peak plasma concentration (Tmax) reached in approximately 4-6 hours.
Metabolism
Primarily hepatic, via cytochrome P450 enzyme CYP3A4/5, with minor contributions from CYP2B6.
Side Effects
Contraindications
- •Hypersensitivity to crizotinib or any excipients.
- •Severe hepatic impairment (caution and dose adjustment required).
Drug Interactions
0
Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin): May increase crizotinib plasma concentrations; avoid co-administration or reduce crizotinib dose.
1
Strong CYP3A inducers (e.g., rifampin, phenytoin): May decrease crizotinib plasma concentrations; avoid co-administration.
2
QT-prolonging agents: Increased risk of QT prolongation; monitor ECG.
3
CYP3A substrates (e.g., midazolam, cyclosporine): Crizotinib is a moderate CYP3A inhibitor; monitor for increased toxicity of co-administered CYP3A substrates.
Storage
Store at room temperature (20°C to 25°C). Protect from moisture and heat. Keep out of reach of children.
Overdose
No specific antidote for crizotinib overdose. Manage overdose symptomatically and provide supportive care. Monitor for hepatotoxicity, pulmonary events, QT prolongation, and ophthalmic adverse reactions.
Pregnancy & Lactation
Pregnancy: May cause fetal harm; advise pregnant women of the potential risk. Use effective contraception during treatment and for at least 45 days after the last dose. Lactation: Avoid breastfeeding during treatment and for 45 days after the last dose, as excretion into breast milk is unknown.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24-36 months from the date of manufacture, varies by manufacturer.
Availability
Hospital pharmacies, oncology centers
Approval Status
FDA Approved (2011)
Patent Status
Varies by region (Original patent holder Pfizer)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
